Next generation sequencing as the new gold standard for minimal residual disease detection in B-ALL

Cheng et al. (1) in their study explored the use of the next-generation sequencing (NGS) technology to evaluate post-remission minimal residual disease (MRD) in B acute lymphoblastic leukaemia/lymphoma (B-ALL) patients and its potential to be implemented in clinical settings. The authors propose an NGS-based method with an applicability of around 90% of B-ALL patients and a sensitivity of up to 10−6 and losing only 6.25% of the cases where leukaemia-specific clonotypes were not identified.